Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05052372 · ClinicalTrials.gov registry record
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
A clinical trial, sponsored by xCures.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05052372: Clinical Trial study, sponsored by xCures.
NCT05052372 is a clinical trial that was terminated before completion, run by xCures. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05052372 was terminated before completion, sponsored by xCures.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.
Primary Outcome
Specimen collection will be performed at the following timepoints to assess clinical response while being treated with erdafitinib: 1. Baseline (prior to or within 7 days of starting erdafitinib) 2. Suspicion of progression (optional) 3. Post-progression
Interventions
- DRUG Balversa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-11-21 |
| Est. Completion | 2022-12-20 |
Why NCT05052372 stopped before completion
NCT05052372 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Balversa is the first listed.
NCT05052372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05052372 about?
NCT05052372 is a clinical study titled "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib". Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This stud...
What is the current status of trial NCT05052372?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2021-11-21. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT05052372?
The interventions under investigation include: Balversa (DRUG).
Who is sponsoring clinical trial NCT05052372?
This trial is sponsored by xCures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI